Influence of ABCB1 gene polymorphisms on the pharmacokinetics of verapamil among healthy Chinese Han ethnic subjects

British Journal of Clinical Pharmacology

Volumn 68, Issue 3, 2009, Pages 395-401

  Zhao, Li Mei ^a   He, Xiao Jing ^a   Qiu, Feng ^a   Sun, Ya Xin ^a   Li Ling, Jesse ^a,b  

^a CHINA MEDICAL UNIVERSITY   (China)

^b NORTHEASTERN UNIVERSITY   (China)

Author keywords

ABCB1; Pharmacokinetics; SNP; Verapamil

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; VERAPAMIL;

ALLELE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHINESE; CONTROLLED STUDY; DIET RESTRICTION; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; DRUG EFFICACY; ETHNIC DIFFERENCE; GENOTYPE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM PLASMA CONCENTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; ASIAN CONTINENTAL ANCESTRY GROUP; CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GENOTYPE; HALF-LIFE; HUMANS; MALE; P-GLYCOPROTEIN; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; VERAPAMIL; YOUNG ADULT;

EID: 69949112838     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2009.03467.x     Document Type: Article

References (49)

1. Halperin AK, Cubeddu LX. The role of calcium channel blockers in the treatment of hypertension. Am Heart J 1986 111 : 363 382.
2. McAllister RG Jr., Hamann SR, Blouin RA. Pharmacokinetics of calcium-entry blockers. Am J Cardiol 1985 55 : 30B 40B.
3. Dadashzadeh S, Javadian B, Sadeghian S. The effect of gender on the pharmacokinetics of verapamil and norverapamil in humans. Biopharm Drug Dispos 2006 27 : 329 334.
4. Choi DH, Shin WG, Choi JS. Drug interaction between oral atorvastatin and verapamil in healthy subjects: effects of atorvastatin on the pharmacokinetics of verapamil and norverapamil. Eur J Clin Pharmacol 2008 64 : 445 449.
5. Choi JS, Han HK. The effect of quercetin on the pharmacokinetics of verapamil and its major metabolite, norverapamil in rabbits. J Pharm Pharmacol 2004 56 : 1537 1542.
6. Ho PC, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol 2000 56 : 693 698.
7. Kerb R, Hoffmeyer S, Brinkmann U. ABC drug transporters: hereditary polymorphisms and pharmacological impact in MDR1, MRP1 and MRP2. Pharmacogenomics 2001 2 : 51 64.
8. Sakaeda T, Nakamura T, Okumura K. MDR1 genotype-related pharmacokinetics and pharmacodynamics. Biol Pharm Bull 2002 25 : 1391 1400.
9. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist 2003 8 : 411 424.
10. Hollt V, Kouba M, Dietel M, Vogt G. Stereoisomers of calcium antagonists which differ markedly in their potencies as calcium blockers are equally effective in modulating drug transport by p-glycoprotein. Biochemistry and. Pharmacology 1992 40 : 2601 2608.
11. Chiou WL, Chung SM, Wu TC, Ma C. A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int J Clin Pharmacol Ther 2001 39 : 93 101.
12. Yumoto R, Murakami T, Takano M. Differential effect of acute hepatic failure on in vivo and in vitro P-glycoprotein functions in the intestine. Pharm Res 2003 20 : 765 771.
13. Bosch TM, Meijerman I, Beijnen JH, Schellens JH. Genetic polymorphisms of drug-metabolizing enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin Pharmacokinet 2006 45 : 253 285. (Pubitemid 43327492)
14. Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther 2001 70 : 311 316.
15. Gerloff T, Schaefer M, Johne A, Oselin K, Meisel C, Cascorbi I, Roots I. MDR1 genotypes do not influence the absorption of a single oral dose of 1 mg digoxin in healthy white males. Br J Clin Pharmacol 2002 54 : 610 616.
16. Johne A, Kopke K, Gerloff T, Mai I, Rietbrock S, Meisel C, Hoffmeyer S, Kerb R, Fromm MF, Brinkmann U, Eichelbaum M, Brockmoller J, Cascorbi I, Roots I. Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene. Clin Pharmacol Ther 2002 72 : 584 594.
17. Kurata Y, Ieiri I, Kimura M, Morita T, Irie S, Urae A, Ohdo S, Ohtani H, Sawada Y, Hiquchi S, Otsubo K. Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein. Clin Pharmacol Ther 2002 72 : 209 219.
18. Verstuyft C, Schwab M, Schaeffeler E, Kerb R, Brinkmann U, Jaillon P, Funck-Brentano C, Becquemont L. Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur J Clin Pharmacol 2003 58 : 809 812. (Pubitemid 36577811)
19. Verstuyft C, Strabach S, El-Morabet H, Kerb R, Brinkmann U, Dubert L, Jaillon P, Funck-Brentano C, Truqnan G, Becquemont L. Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition. Clin Pharmacol Ther 2003 73 : 51 60.
20. Keller F, Rietbrock N. Bioavailability of digoxin: some pitfalls and problems. Int J Clin Pharmacol Biopharm 1977 15 : 549 556.
21. Sakaeda T, Nakamura T, Horinouchi M, Kakumoto M, Ohmoto N, Sakai T, Morita Y, Tamura T, Aoyama N, Hirai M, Kasuqa M, Okumura K. MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects. Pharm Res 2001 18 : 1400 1404.
22. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001 70 : 189 199.
23. Horinouchi M, Sakaeda T, Nakamura T, Morita Y, Tamura T, Aoyama N, Kasuga M, Okumura K. Significant genetic linkage of MDR1 polymorphisms at positions 3435 and 2677: functional relevance to pharmacokinetics of digoxin. Pharm Res 2002 19 : 1581 1585.
24. Chowbay B, Cumaraswamy S, Cheung YB, Zhou Q, Lee EJ. Genetic polymorphisms in MDR1 and CYP3A4 genes in Asians and the influence of MDR1 haplotypes on cyclosporin disposition in heart transplant recipients. Pharmacogenetics 2003 13 : 89 95.
25. Tan EK, Chan DK, Ng PW, Woo J, Teo YY, Tang K, Wong LP, Chong SS, Tan C, Shen H, Zhao Y, Lee CG. Effect of MDR1 haplotype on risk of Parkinson disease. Arch Neurol 2005 62 : 460 464.
26. Sata F, Sapone A, Elizondo G, Stocker P, Miller VP, Zheng W, Raunio H, Crespi CL, Gonzalez FJ. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 2000 67 : 48 56.
27. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, Mayer P, Weinrvb I, Guida M, Hopkins PJ, Warner N, Hall J. Population distribution and effects on drug metabolism of a genetic variant in the 5′promoter region of CYP3A4. Clin Pharmacol Ther 1999 66 : 288 294.
28. Jin Y, Wang YH, Miao J, Li L, Kovacs RJ, Marunde R, Hamman MA, Phillips S, Hilligoss J, Hall SD. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007 82 : 579 585.
29. Langaee TY, Gong Y, Yarandi HN, Katz DA, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Association of CYP3A5 polymorphisms with hypertension and antihypertensive response to verapamil. Clin Pharmacol Ther 2007 81 : 386 391.
30. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boquski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genet 2001 27 : 383 391.
31. Kurzawski M, Pawlik A, Gornik W, Drozdzik M. Frequency of common MDR1 gene variants in a Polish population. Pharmacol Rep 2006 58 : 35 40.
32. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999 286 : 487 491.
33. Anglicheau D, Thervet E, Etienne I, Hurault de Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P. CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 2004 75 : 422 433.
34. Kurzawski M, Bartnicka L, Florczak M, Górnik W, Drozdzik M. Impact of ABCB1 (MDR1) gene polymorphism and P-glycoprotein inhibitors on digoxin serum concentration in congestive heart failure patients. Pharmacol Rep 2007 59 : 107 111. (Pubitemid 46522710)
35. Mai I, Störmer E, Goldammer M, Johne A, Krüger H, Budde K, Roots I. MDR1 haplotypes do not affect the steady-state pharmacokinetics of cyclosporine in renal transplant patients. J Clin Pharmacol 2003 43 : 1101 1107.
36. Mai I, Perloff ES, Bauer S, Goldammer M, Johne A, Filler G, Budde K, Roots I. MDR1 haplotypes derived from exons 21 and 26 do not affect the steady-state pharmacokinetics of tacrolimus in renal transplant patients. Br J Clin Pharmacol 2004 58 : 548 553.
37. Kim KA, Park PW, Park JY. Effect of ABCB1 (MDR1) haplotypes derived from G2677T/C3435T on the pharmacokinetics of amlodipine in healthy subjects. Br J Clin Pharmacol 2007 63 : 53 8.
38. McAllister RG Jr., Kirsten EB. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses. Clin Pharmacol Ther 1982 31 : 418 426.
39. Horne C, Stenzhorn G, Blume H, Knauf H, Mutschler E. Bioavailability study of two different verapamil formulations. Arch Pharm (Weinheim) 1992 325 : 531 536.
40. Hla KK, Latham AN, Henry JA. Influence of time of administration on verapamil pharmacokinetics. Clin Pharmacol Ther 1992 51 : 366 370.
41. Sohn JW, Lee SY, Lee SJ, Kim EJ, Cha SI, Kim CH, Lee JT, Jung TH, Park JY. MDR1 polymorphisms predict the response to etoposide-cisplatin combination chemotherapy in small cell lung cancer. Jpn J Clin Oncol 2006 36 : 137 141.
42. Pan W, Ryu JY, Shon JH, Song IS, Liu KH, Sunwoo YE, Kang W, Shin JG. Dietary salt dose not influence the disposition of verapamil enantiomers in relation to efflux transporter ABCB1 genetic polymorphism in healthy Korean subjects. Xenobiotica 2008 38 : 422 434.
43. Harder S, Thurmann P, Siewert M, Blume H, Huber TH, Rietbrock N. Pharmacodynamic profile of verapamil in relation to absolute bioavailability: investigations with a conventional and controlled release formulation. J Cardiovasc Pharmacol 1991 17 : 207 212.
44. Hoffmeyer S, Burk O, von Richter O, Arnold HP, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. Functional polymorphisms of the human multidrug-resistance gene:multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci U S A 2000 97 : 3473 3478.
45. Neuhoff S, Langguth P, Dressler C, Andersson TB, Regardh CG, Spahn-Langguth H. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: Drugs and analogs, stereoisomers and metabolites. Int J Clin Pharmacol Ther 2000 38 : 168 179.
46. Gruber A, Peterson C, Reizenstein P. D-verapamil and L-verapamil are equally effective in increasing vincristine accumulation in leukemic cells in vitro. Int J Cancer 1988 41 : 224 226.
47. Plumb JA, Milroy R, Kaye SB. The activity of verapamil as a resistance modifier in vitro in drug resistant human tumor cell lines is not stereospecific. Biochem Pharmacol 1990 39 : 787 792.
48. Keilhauer C, Emling F, Raschak M, Gries J, Schlick E. The use of R-verapamil (R-VPM) is superior to racemic VPM in breaking multidrug resistance (MDR) of malignant cells. Proc Am Assoc Cancer Res 1989 30 : 503 (Abstract).
49. Takane H, Kobayashi D, Hirota T, Kiqawa J, Terakawa N, Otsubo K, Ieiri I. Haplotype-oriented genetic analysis and functional assessment of promoter variants in the MDR1 (ABCB1) gene. J Pharmacol Exp Ther 2004 311 : 1179 1187.